

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approvals for drug production and registration for Blonanserin Tablets (4mg), Paracetamol and Mannitol Injection (100ml:1000mg) and Levofloxacin Injection (20ml:0.5g) from the National Medical Products Administration of China. Blonanserin Tablets is under type 4 chemical drug and the other two injections are under type 3 chemical drug, all being regarded as passing the consistency evaluations.

The Group’s Blonanserin Tablets is the first of such approval for the PRC entities, which is mainly used in treatment of schizophrenia. Regarding the Group’s Paracetamol and Mannitol Injection, the indication approved is for relieving fever in adults, which is the first of such approval for the PRC entities. Levofloxacin Injection is mainly used in treatment or prevention of infections which have been proven or highly suspected to be caused by susceptible bacteria.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 20 June 2022

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.